Subtype of compact follicular thyroid carcinoma in a canine
DOI:
https://doi.org/10.26605/medvet-v17n1-5184Keywords:
neoplasm; malignancy; cytology; histopathologyAbstract
Thyroid tumors represent 4% of neoplasms in dogs, being the most common carcinomas, corresponding to 88% of thyroid tumors. These are characterized by their rapid growth and invasiveness. Due to this, the present study aims to report a case of compact follicular subtype thyroid carcinoma in a canine, with emphasis on its clinical, diagnostic and therapeutic aspects. A seven-year-old male, neutered, mixed-breed canine, weighing 27 kg, complained of dyspnea for 60 days, weight loss, dysphonia and increased volume in the topography of the thyroid gland was treated. Ultrasound-guided fine-needle cytology was performed with a diagnosis suggestive of thyroid carcinoma. Afterwards, computed tomography was requested for surgical planning. As treatment, we chose to use toceranib phosphate, 3.25 mg.kg-1, three times a week, associated with piroxicam 0.3 mg.kg-1, once a day, for 60 days, in which he presented reduction in the size of the mass and clinical signs, so the patient underwent surgical resection and a tissue fragment was sent for histopathological analysis, which confirmed the diagnosis of compact follicular subtype carcinoma. Postoperatively, the patient's clinical condition worsened and, despite intensive management, died. Thyroid neoplasms have aggressive biological behavior and low survival, and adjuvant therapy with toceranib phosphate it was efficient in reducing the neoplastic mass. Still, the cytological examination is a crucial screening tool for diagnostic conduction, however, the definitive diagnosis can only be performed by histopathological analysis.Downloads
References
Alleman, A.R.; Choi, U.S. Endocrine system. In: Canine and feline citology: a color atlas and interpretation guide. 2nd ed. Raskin, R.E.; Meyer, D.J (Eds). St Louis: Saunders Elsevier, 2010. p. 383-394.
Barber, L.G. Thyroid tumors in dogs and cats. Veterinary Clinics of North America: Small Animal Practice, 37: 755-773, 2007.
Campos, M.; Ducatelle, R.; Kooistra, H.; Rutteman, G.; Duchateau, L.; Polis, I.; Daminet, S. Immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma. Journal of Veterinary Internal Medicine, 28: 564-570, 2014.
Chan, C. Palladia® in Pets. The Pet Oncologist, 2020. Disponível em: <https://www.thepetoncologist.com/blog/faqs-palladia-in-pets>. Acesso em: 25ago22.
Deitz, K.; Gilmour, L.; Wilke, V.; Riedesel, E. Computed tomographic appearance of canine thyroid tumours. Journal of Small Animal Practice, 55: 323-329, 2014.
Ernandes Neto, M.; Tagliarini, J.V.; López, B.E.; Padovani, C.R.; Marques, M.D.A., Castilho, E.C.; Mazeto, G.M.F.S. Factors influencing thyroidectomy complications. Brazilian Journal of Otorhinolaryngology, 78: 63-69, 2012.
Fossum, T.W. Cirurgia de pequenos animais. 4ª. ed. Rio de Janeiro: Elsevier, 2014. 1640 p.
Goldhaber, S.Z. Echocardiography in the management of pulmonary embolism. Annals of Internal Medicine, 136: 691-700, 2002.
Herring, E.S.; Smith, M.M.; Robertson, J.L. Lymph node staging of oral and maxillofacial neoplasms in 31 dogs and cats. Journal of Veterinary Dentistry, 19: 122-126, 2002.
Liu, J.W.; Chen, C.; Loh, E.W.; Chu, C.C.; Wang, M.Y.; Ouyang, H.J.; Chang, Y.T.; Zhuang, W.Z.; Chou, C.W.; Huang, D.J. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 34: 795-803, 2018.
London, C.; Mathie, T.; Stingle, N.; Clifford, C.; Haney, S.; Klein, M.K.; Beaver, L.; Vickery, K.; Vail, D.M.; Hershey, B. Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours. Veterinary and Comparative Oncology, 10: 194-205, 2012.
Mooney, C. Hipertireoidismo em cães. In: Money, C.T.; Peterson, M.E. (Eds.). Manual de endocrinologia em cães e gatos. V.4. Roca: São Paulo, 2015. p.139-148.
Nelson, R.W. Distúrbios endócrinos. In: Nelson, R.W.; Couto, G.C. (Ed.). Medicina interna de pequenos animais. 5ª. ed. Rio de Janeiro: Elsevier, 2015. p. 713-857.
Pessina, P.; Castillo, V.; Sartore, I.; Borrego, J.; Meikle, A. Semiquantitative immunohistochemical marker staining and localization in canine thyroid carcinoma and normal thyroid gland. Veterinary and Comparative Oncology, 14: e102-e112, 2016.
Rosol, T.J.; Meuten, D.J. Tumors of the endocrine glands. In: Meuten, D.J. Tumors in domestic animals. 5th ed. Ames: John Wiley & Sons, 2017. p. 766-833.
Sheppard?Olivares, S.; Bello, N.M.; Wood, E.; Szivek, A.; Biller, B.; Hocker, S.; Wouda, R. M. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009?2018). Veterinary and Comparative Oncology, 18: 519-527, 2020.
Théon, A.P.; Marks, S.L.; Feldman, E.S.; Griffey, S. Prognostic factors and patterns of treatment failure in dogs with unresectable differentiated thyroid carcinomas treated with megavoltage irradiation. Journal of the American Veterinary Medical Association, 216: 1775-1779, 2000.
Tochetto, C.; Silva, T.M.; Fighera, R.A.; Irigoyen, L.F.; Kommers, G.D. Neoplasmas da tireoide em cães: 26 casos. Pesquisa Veterinária Brasileira, 37: 1460-1466, 2017.
Wouda, R.; Miller, M.; Chon, E.; Stein, T. Efeitos clínicos da administração de vinorelbina no tratamento de vários tipos de tumor maligno em cães: 58 casos (1997-2012). Journal of the American Veterinary Medical Association, 246: 1230-1237, 2015.
Wucherer, K.L.; Wilke, V. Thyroid cancer in dogs: an update based on 638 cases (1995–2005). Journal of the American Animal Hospital Association, 46: 249-254, 2010.
Yancey, M.; Merritt, D.; Lesman, S.; Boucher, J.; Michels, G. Pharmacokinetic properties of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. Journal of Veterinary Pharmacology and Therapeutics, 33: 162-171, 2010.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
A Revista de Medicina Veterinária permite que o autor retenha os direitos de publicação sem restrições, utilizando para tal a licença Creative Commons CC BY-NC-SA 4.0.
De acordo com os termos seguintes:
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
NãoComercial — Você não pode usar o material para fins comerciais.
CompartilhaIgual — Se você remixar, transformar, ou criar a partir do material, tem de distribuir as suas contribuições sob a mesma licença que o original.
Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.